Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
An Open-Label, Non-Randomized, Uncontrolled, Single-dose Pilot Study of VGR-R01 in Patients with Bietti Crystalline Dystrophy.
VGR-R01 is a novel AAV vector carrying the human CYP4v2 coding sequence. This study is intended to evaluate the safety and tolerability of a single subretinal administration of VGR-R01. All subjects will undergo 365(±7) days of safety observation and will be encouraged to enroll in an extension study to evaluate the long-term safety of VGR-R01 for a total of five years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| VGR-R01 | Experimental | Subretinal injection of VGR-R01 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| VGR-R01 | Drug | Gene Replacement Therapy |
|
| Measure | Description | Time Frame |
|---|---|---|
| Incidence of adverse events | An adverse event (AE) is any untoward medical occurrence in a clinical investigation participant administered a product; the event will not need to have a causal relationship with the treatment. | Baseline up to Day 365 |
| Incidence of serious adverse events | A serious adverse event (SAE) is any untoward medical occurrence at any dose that resulted in death; life threatening; require inpatient hospitalization or prolongation of existing hospitalization; result in persistent or significant disability/incapacity; result in congenital anomaly/birth defect. | Baseline up to Day 365 |
| Number of Participants with Clinically Significant Change from Baseline in Vital Signs | Vital signs (temperature, respiratory rate, pulse rate, systolic and diastolic blood pressure) will be obtained with participant in the seated position, after having sat calmly for at least 5 minutes. Clinical significance of vital signs will be determined at the investigator's discretion. | Baseline up to Day 365 |
| Number of Participants with Clinically Laboratory Abnormalities | Laboratory Tests will include hematology, coagulation, blood chemistry, urinalysis, serology, and pregnancy test, etc. If any potential changes accompanied by clinical symptoms, or results in a change of medical intervention, the findings will be considered as clinically significant based on investigator's decision. | Baseline up to Day 365 |
| Number of Participants with Clinically Significant Change from Baseline in Ophthalmic Examination Findings | Ophthalmic Examination will include BCVA, IOP, slitlamp examination, angiography and SD-OCT, etc. If any potential changes accompanied by clinical symptoms, or results in a change of medical intervention, the findings will be considered as clinically significant based on investigator's decision. |
| Measure | Description | Time Frame |
|---|---|---|
| Best-Corrected Visual Acuity (BCVA) | BCVA will be assessed for both eyes using the Early Treatment of Diabetic Retinopathy Study (ETDRS) visual acuity (VA) chart. BCVA test should be performed prior to pupil dilation, and distance refraction should be carried out before BCVA is measured. Initially, letters are read at a distance of 4 meters from the chart. If <20 letters are read at 4 meters, testing at 1 meter should be performed. BCVA is to be reported as number of letters read correctly by the participant using the ETDRS Scale (ranging from 0 to 100 letters) in the study eye. The lower the number of letters read correctly on the eye chart, the worse the vision (or visual acuity). An increase in the number of letters read correctly means that vision has improved. |
Not provided
Inclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Wenbin Wei | Contact | 010-58269516 | tr_weiwenbin@163.com | |
| Xiuli Zhao | Contact | 010-58268486-8008 | xiulizhao@medmail.com.cn |
| Name | Affiliation | Role |
|---|---|---|
| Wenbin Wei | Vice President of Beijing Tongren Hospital | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Beijing Tongren Hospital | Recruiting | Beijing | Beijing Municipality | 100730 | China |
IPD will be shared with other researchers when VGR-R01 is fully approved.
IPD will be shared with other researchers when VGR-R01 is fully approved.
IPD will be shared with other researchers when VGR-R01 is fully approved.
Not provided
Not provided
| ID | Term |
|---|---|
| C535440 | Bietti Crystalline Dystrophy |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Baseline up to Day 365 |
| Up to Day 365 |
| Changes from baseline in Visual Field indexes | The outcome measeures will be assessed by Humphery perimetry | Up to Day 365 |
| Changes from baseline in Microperimetry indexes | The Microperimetry will be applied to assess the retinal sensitivity and the fixation behaviour. | Up to Day 365 |
| Changes from baseline in ERG indexes | The measeurement will be performed based on the standards of International Society for Clinical Electrophysiology of Vision (ISCEV) | Up to Day 365 |
| Changes from baseline in m-ERG indexes | The measeurement will be performed based on the standards of International Society for Clinical Electrophysiology of Vision (ISCEV) | Up to Day 365 |
| Change from Baseline in NEI Visual Function Questionnaire (NEI-VFQ-25) | NEI-VFQ-25 questionnaire measures dimensions of self-reported vision-targeted health status that are most important to persons with eye disease. Total score ranges from 0-100, where a score of 0 represents the worst outcome and 100 represents the best outcome. | Up to Day 365 |
| Changes from Baseline in Spectral Domain Optical Coherence Tomography (SD-OCT) | Up to Day 365 |
| Changes from Baseline in Optical Coherence Tomography Angiography(OCT-A) | Up to Day 365 |